BarbaraJaneKlenckeMD

Oncology • South San Francisco, CA

Breast Cancer, HIV/AIDS Related, Hematologic Oncology

SVP, Development, Onyx Pharmaceuticals

Join to view full profile

Dr. Klencke is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Klencke's full profile

Already have an account?

Office
Onyx Pharmaceuticals
249 E Grand Ave
South San Francisco, CA 94080
Phone+1 650-266-1008

Education & Training

University of California (San Francisco)Internship, Internal Medicine, 1990 - 1991
University of California San Diego School of MedicineClass of 1990

Clinical Trials

EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma Start of enrollment: 2000 Sep 01
Terminated
Phase 1
A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme) Start of enrollment: 2003 Jul 01
Completed
Phase 2

Publications & Presentations

PubMed

54 citations
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conju...
Manish Gupta, Patricia LoRusso, Bei Wang, Joo-Hee Yi, Howard A. Burris
Journal of Clinical Pharmacology. 2012-05-01
524 citations
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior ...
Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja, Charles L. Vogel, Rachel A. Borson
Journal of Clinical Oncology. 2011-02-01
90 citations
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
W. K. Alfred Yung, James J. Vredenburgh, Timothy F. Cloughesy, Phioanh L. Nghiemphu, Barbara Klencke
Neuro-Oncology. 2010-10-01

Press Mentions

eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateNovember 8th, 2021
Sierra Oncology Hosting KOL Panel Event to Discuss Momelotinib Data Presented at EHA 2021June 14th, 2021
FDA Grants Fast-Track Designation to Bone Marrow Cancer DrugJune 7th, 2019
Join now to see all

Grant Support

Plasmid DNA Vaccine To HPV-16 For Anal DysplasiaNational Center For Research Resources2000–2002
ONYX-015 For HIV Associated Preinvasive Anal CarcinomaNational Center For Research Resources2000–2002